BioSpace News Archive

To speed rapid and effective response efforts to the mounting COVID-19 global health crisis, the American National Standards Institute has added a new suite of key international standards to the ANSI portal, Freely Available ISO Standards to Help Address COVID-19 Crisis.

Nevro Corp. announced that the underwriter of each of Nevro’s previously announced concurrent public offerings of 1,625,000 shares of its common stock and $165,000,000 aggregate amount of its 2.75% convertible senior notes due 2025 has fully exercised its option to purchase an additional 243,750 shares of Nevro’s common stock at a public offering price of $84.00 per share

Miami-Dade County Received 20,000 DMGtests This Week to Screen First Responders, Support Random Population Survey

In the midst of the global COVID-19 pandemic and in an effort to ensure access to protective gear to first responders, Galls – a national distributor of equipment to state and local first responders – has pledged to offer N95 and other protective masks to its public safety partners at no profit to the company.

The ASHP asked the Trump Administration to take steps, including releasing drugs from the Strategic National Stockpile to states hardest hit by the COVID-19 pandemic and increasing the quota for new production of opioids, to address critical shortages of medications needed to treat COVID-19 patients.

Aligned with its mission to improve and save lives with diagnostics, Ortho Clinical Diagnostics announced it is launching to market its SARS-CoV-2 antibody test—the VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack.

ICON plc, (NASDAQ: ICLR) a leading global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSE:PFE)

With alarming new rates of infection and transmission, family physicians implore Americans to just stay home

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has received notification from its European Authorized Representative,

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce it has been added to the list of Commercial Manufacturers and Laboratories which have notified the U.S. Food and Drug Administration